Skip to main content

Table 2 Model-estimated proportion of patients with episodic and chronic migraine with ≥ 50% response

From: Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies

Response rate

Galcanezumab 120 mg

(N = 436)

Galcanezumab 240 mg

(N = 428)

Placebo

(N = 875)

Episodic migraine

 Overall 6 months

60.8%

58.7%

37.2%

  Odds ratio (95% CI)

2.6 (2.2, 3.1)*

2.4 (2.0, 2.8)*

 Month 1, %

50.9%

47.2%

23.8%

  Odds ratio (95% CI)

3.3 (2.6, 4.2)*

2.9 (2.2, 3.7)*

 Month 6, %

65.7%

63.2%

44.3%

  Odds ratio (95% CI)

2.4 (1.9, 3.1)*

2.2 (1.7, 2.8)*

Chronic migraine

Galcanezumab 120 mg

(N = 273)

Galcanezumab 240 mg

(N = 274)

Placebo

(N = 538)

 Overall 3 months

27.6%

27.5%

15.4%

  Odds ratio (95% CI)

2.1 (1.6, 2.8)*

2.1 (1.6, 2.8)*

 Month 1, %

23.7%

21.2%

9.9%

  Odds ratio (95% CI)

2.8 (1.9, 4.2)*

2.5 (1.7, 3.6)*

 Month 3, %

31.9%

34.0%

22.4%

  Odds ratio (95% CI)

1.6 (1.2, 2.3)

1.8 (1.3, 2.5)*

  1. Abbreviations: CI confidence interval
  2. *p < 0.001 versus placebo
  3. p ≤ 0.004 versus placebo